Matrix metalloproteinases: a potential therapeutic target in atherosclerosis

Mustapha Rouis1

  • 1Institut National de la Santé et de la Recherche Médicale (INSERM) U-545, Nuclear receptors, lipoproteins and atherosclerosis, Institut Pasteur de Lille, France. Mustapha.Rouis@pasteur-lille.fr

Current Drug Targets. Cardiovascular & Haematological Disorders
|March 1, 2006
PubMed
Summary

Matrix metalloproteinases (MMPs) from macrophages weaken atherosclerotic plaques, increasing rupture risk. Selective MMP inhibition or gene transfer may offer better atherosclerosis treatment than current broad-spectrum inhibitors.